aspartylglucosaminuria

MeSH: D054880ORPHA: 93

Overview

disease that is characterized by a decline in mental functioning, accompanied by an increase in skin, bone and joint issues

Available Treatments (0)

No treatments linked yet

Clinical trials or compassionate use may be available — consult a specialist.

Clinical Presentation

Signs and symptoms associated with aspartylglucosaminuria, sourced from HPO and Orphanet clinical annotations.

Gingival overgrowthMandibular prognathiaHypertelorismWide nasal bridgeDelayed speech and language developmentIntellectual disabilityUmbilical herniaAbnormal facial shapeAbnormal speech patternScoliosisShort noseAbnormality of amino acid metabolismMicrotiaAspartylglucosaminuriaThick vermilion borderDyskinesiaLarge faceMacroorchidismMacroglossiaAbnormality of the dentitionCoarse facial featuresCarious teethPectus carinatumThickened calvariaAbnormal cortical bone morphologyAnterior beaking of lumbar vertebraeAbnormal morphology of ulnaInguinal herniaChronic otitis mediaAtypical behaviorSeizureArthritisJoint stiffnessSplenomegalyPes planusMalabsorptionRecurrent respiratory infectionsHepatomegalySleep disturbanceDelayed skeletal maturationAbnormal vertebral morphologyBeaking of vertebral bodiesVascular skin abnormality

Classification & Codes

MeSH Code

D054880

Orphanet Code

ORPHA:93
aspartylglucosaminuria
MeSHD054880
OrphanetORPHA:93
Treatments0 drug(s)
Symptoms on record43 signs
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO